270 related articles for article (PubMed ID: 37197625)
21. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K; Ling X; Jiang X; Ma J; Zhu J
Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
[TBL] [Abstract][Full Text] [Related]
22. [Construction of Lung Adenocarcinoma Prognosis Model and Drug Sensitivity Analysis Based on Cuproptosis Related Genes].
Sun J; Zhang H; Liu H; Dong Y; Wang P
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):591-604. PubMed ID: 37752539
[TBL] [Abstract][Full Text] [Related]
23. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
24. Cuproptosis/ferroptosis-related gene signature is correlated with immune infiltration and predict the prognosis for patients with breast cancer.
Li J; Zhang W; Ma X; Wei Y; Zhou F; Li J; Zhang C; Yang Z
Front Pharmacol; 2023; 14():1192434. PubMed ID: 37521466
[No Abstract] [Full Text] [Related]
25. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
26. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma.
Xu X; Liang JH; Xu QC; Yin XY
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046
[TBL] [Abstract][Full Text] [Related]
27. Cuproptosis-related gene signatures for predicting prognosis of lung adenocarcinoma.
Ye W; Huang Y; Li X
Medicine (Baltimore); 2022 Oct; 101(40):e30446. PubMed ID: 36221373
[TBL] [Abstract][Full Text] [Related]
28. Development of a ferroptosis-based model to predict prognosis, tumor microenvironment, and drug response for lung adenocarcinoma with weighted genes co-expression network analysis.
Cheng T; Shan G; Yang H; Gu J; Lu C; Xu F; Ge D
Front Pharmacol; 2022; 13():1072589. PubMed ID: 36467089
[No Abstract] [Full Text] [Related]
29. Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma.
Wang Z; Yao J; Dong T; Niu X
J Immunol Res; 2022; 2022():2756611. PubMed ID: 36281357
[TBL] [Abstract][Full Text] [Related]
30. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation.
Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J
Front Oncol; 2022; 12():1030802. PubMed ID: 36620545
[TBL] [Abstract][Full Text] [Related]
31. Significance of Spliceosome-Related Genes in the Prediction of Prognosis and Treatment Strategies for Lung Adenocarcinoma.
Yang Y; Huang T; Fan Y; Lu H; Shao J; Wang Y; Shen A
Biomed Res Int; 2022; 2022():1753563. PubMed ID: 36389112
[TBL] [Abstract][Full Text] [Related]
32. A novel cuproptosis-related signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma.
Cui Y; Zhang LJ; Xu YJ; Liu MY
Am J Transl Res; 2023; 15(6):3942-3959. PubMed ID: 37434829
[TBL] [Abstract][Full Text] [Related]
33. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
Xu M; Mu J; Wang J; Zhou Q; Wang J
Front Oncol; 2022; 12():961213. PubMed ID: 35965536
[TBL] [Abstract][Full Text] [Related]
34. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.
Li N; Jia W; Wang J; Shao Q; Feng X; Li Z; Sun W; Kang M; Hu D; Xing L; Zhan X
EPMA J; 2024 Jun; 15(2):345-373. PubMed ID: 38841624
[TBL] [Abstract][Full Text] [Related]
35. Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation.
Liu Z; Zhu F; Zhang P; Qian B; Liu W; Xiao Y; Chen N; He Q; Xiao J
Front Genet; 2022; 13():1074981. PubMed ID: 36506302
[No Abstract] [Full Text] [Related]
36. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis.
Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L
BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550
[TBL] [Abstract][Full Text] [Related]
37. A novel defined cuproptosis-related gene signature for predicting the prognosis of colon adenocarcinoma.
Luo B; Lin J; Ni A; Cai W; Yu X; Wang M
Front Oncol; 2022; 12():927028. PubMed ID: 36505872
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of early-stage lung adenocarcinoma patients.
Tang Y; Li Q; Zhang D; Ma Z; Yang J; Cui Y; Zhang A
Front Genet; 2022; 13():977156. PubMed ID: 36186452
[No Abstract] [Full Text] [Related]
39. Identification of a 5-Gene Cuproptosis Signature Predicting the Prognosis for Colon Adenocarcinoma Based on WGCNA.
Wang D; Yang F; Han G; Zhang J; Wang H; Xiao Z; Chen W; Li P
Technol Cancer Res Treat; 2024; 23():15330338241250285. PubMed ID: 38802999
[No Abstract] [Full Text] [Related]
40. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
